

PATENT O2550D 001240HS

Attorney Docket No.: 02558P-001340US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

James Blake et al.

Application No.: 09/733,239

Filed: December 8, 2000

For: CYSTEINE THIOL-PROTECTED

PEPTIDES FOR USE IN IMMUNOASSAYS

Customer No.: 20350

Confirmation No.: 1694

Examiner: Emily M. Le

Art Unit: 1648

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The reference cited on attached form PTO/SB/08B is being called to the attention of the Examiner. A copy of the reference is enclosed.

The reference was previously submitted in the Information Disclosure Statement filed on August 29, 2001, but not considered on the merits. An English translation of the reference is not available, however, the highlighted portions on page 86 (Diagram 5), page 88

Application No.: 09/733,239

Page 2

(Diagram 7), and page 95 (English Summary) are either in English or show peptide synthetic schematics that use internationally recognized symbols and abbreviations.

It is therefore respectfully requested that the cited reference, particularly the above-specified sections, be expressly considered during the prosecution of this application, and the reference be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and reference cited is prior art merely because it is in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Nicholas V. Sherbina

Reg. No. 54,443

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 206-467-9600 Fax: 206-623-6793

NVS:mmm 60585316 v1



Substitute for form 1449B PAPEMARY				Complete if Known		
				Application Number	09/733,239	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	December 8, 2000	
				First Named Inventor	James Blake	
				Art Unit	1648	
(use as many sheets as necessary)			necessary)	Examiner Name	Emily M. Le	
Sheet	1	of	1	Attorney Docket Number	02558P-001340US	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	AA	ST. GUTTMANN, "Synthèse du glutathion et de l'oxytocine à l'aide d'un nouveau groupe protecteur de la fonction thiol," <i>Helv. Chim. Acta</i> , 49:83-96 at pp. 86 (Diagram 5), 88 (Diagram 7) and 95 (English Summary) (1966).					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.